Physician profile
Whitney Baker
NPI 1225664261
$10,069.03
in general payments reported to CMS, 2019-2025
27 companies · $2,832 in 2025
The $2,832 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,561 · 2022: $853 · 2023: $2,242 · 2024: $2,581 · 2025: $2,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,578 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,577.75 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,123.76 | 2021-2025 | |
| Amgen INC. | $2,016.49 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,419.41 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $753.16 | 2021-2025 | |
| Janssen Biotech, INC. | $640.30 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $507.51 | 2021-2025 | Benlysta |
| Pfizer INC. | $415.70 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $361.19 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $330.41 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $281.27 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $197.68 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $184.13 | 2021-2024 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $149.83 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $113.09 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.73 | 2023-2025 | Cyltezo, Ofev |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $96.78 | 2023-2024 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $96.68 | 2025 | Orencia |
| Genzyme Corporation | $75.78 | 2025 | |
| Alexion Pharmaceuticals, INC. | $38.73 | 2025 | Strensiq |
| Abiomed | $35.46 | 2025 | |
| Argenx US, INC. | $28.63 | 2024 | Vyvgart Hytrulo |
| Mylan Institutional INC. | $19.94 | 2023 | Hulio |
| Sobi, INC | $19.86 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $16.68 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $15.13 | 2022 | |
| Hikma Pharmaceuticals USA | $15.11 | 2021 | |
| Kyowa Kirin, INC. | $14.59 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.